A new study suggests an enzyme unique to Homo sapiens may have made us more competitive water seekers than our closest ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Geneoscopy, Inc ., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that Exact Sciences has withdrawn its motion for a ...

The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ RNA-targeted prophylactic treatment, Dawnzera ...

In the wake of funding cuts to mRNA vaccine research, we revisit a February story about a promising vaccine for pancreatic ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Single-cell proteomics with RNA sequencing uncover hidden gene expression dynamics in stem cell differentiation.

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...